EBMT 2024 | Current research into post-alloSCT maintenance therapy in AML
Ali Bazarbachi, MD, PhD, American University of Beirut, Beirut, Lebanon, gives an overview of current research into maintenance therapy following allogeneic stem cell transplantation (alloSCT) for acute myeloid leukemia (AML). He mentions donor lymphocyte infusion (DLI), as well as post-alloSCT azacitidine maintenance, which has been shown to be effective in several clinical trials (HOVON 156 AML trial; NCT04027309, QUAZAR AML-001; NCT01757535). Dr Bazarbachi also mentions FLT3 inhibition with several agents, including sorafenib, midostaurin, quizartinib, and gilteritinib, for patients with FLT3-mutated AML. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
